diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 2220e30b3..7b58d3030 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -71,6 +71,18 @@ The sarcopenic obesity mechanism creates a pathway where GLP-1s may INCREASE hea WHO issued conditional recommendations (not full endorsements) for GLP-1s in obesity treatment, explicitly acknowledging 'limited long-term evidence.' The conditional framing signals institutional uncertainty about durability of outcomes and cost-effectiveness at population scale. WHO requires countries to 'consider local cost-effectiveness, budget impact, and ethical implications' before adoption, suggesting the chronic use economics remain unproven for resource-constrained health systems. + +### Additional Evidence (challenge) +*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-16* + +International GLP-1 generic competition beginning in 2026 creates price compression trajectory that challenges the 'inflationary through 2035' timeline. Canada's semaglutide patents expired January 4, 2026, with Sandoz, Apotex, and Teva filing immediately. Brazil opens to generics March 2026. China has 17+ generic candidates in Phase 3 with projected pricing of $40-$50/month. India patents expire March 2026. If international generics drive global prices to $50-100/month by 2030 (95%+ below current US list price), the inflection point where volume growth no longer offsets price compression moves significantly earlier than 2035. At $50/month, GLP-1s become unambiguously cost-effective under any payment model, fundamentally changing the net cost calculation. + + +### Additional Evidence (extend) +*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-16* + +US patent timeline extends to 2031-2032 for semaglutide, creating a 5-6 year window where international generic availability creates price arbitrage pressure on US market even before US generics launch. Oral Wegovy launched January 2026 at $149-$299/month (Medicare deal: $245/month), already showing price compression from injectable formulations. Orforglipron (Eli Lilly non-peptide oral GLP-1) could be approved Q2 2026, adding competitive pressure. The gap between international generic availability (2026) and US generic availability (2031-2033) is the critical period where price trajectory determines whether the cost curve inflects earlier than the existing claim assumes. + --- Relevant Notes: diff --git a/inbox/archive/2026-02-01-glp1-patent-cliff-generics-global-competition.md b/inbox/archive/2026-02-01-glp1-patent-cliff-generics-global-competition.md index bbeeccda9..f6364c48c 100644 --- a/inbox/archive/2026-02-01-glp1-patent-cliff-generics-global-competition.md +++ b/inbox/archive/2026-02-01-glp1-patent-cliff-generics-global-competition.md @@ -7,9 +7,13 @@ date: 2026-02-01 domain: health secondary_domains: [internet-finance] format: article -status: unprocessed +status: enrichment priority: medium tags: [glp-1, generics, patent-cliff, global-competition, drug-pricing, market-structure] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -50,3 +54,17 @@ Overview of the GLP-1 generic competition landscape as patents begin expiring in PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: Price trajectory is the key variable the existing claim depends on — if prices decline faster than assumed, the "inflationary through 2035" conclusion may be wrong EXTRACTION HINT: Focus on the price trajectory and its implications for cost-effectiveness under different payment models, especially the international competition pressure + + +## Key Facts +- Semaglutide patents in US and Europe extend to 2031-2032 +- Canada's semaglutide patents expired January 4, 2026 (first G7 nation) +- Sandoz, Apotex, and Teva filed for Canadian generic semaglutide immediately after patent expiry +- Brazil opens to generic semaglutide competition March 2026 +- Biomm + Biocon (India) preparing generic semaglutide for Brazil market +- China has 17+ generic semaglutide candidates in Phase 3 trials +- India semaglutide patents expire March 2026 +- Oral Wegovy launched January 2026 at $149-$299/month +- Medicare negotiated oral Wegovy price: $245/month +- Orforglipron (Eli Lilly) potential approval: Q2 2026 +- Amycretin shows 22% weight loss without plateau in trials